338 filings
Page 11 of 17
8-K
bdsu1y7g
11 Jul 16
Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
12:00am
8-K
xpz29x1 kd
7 Jul 16
Other Events
12:00am
8-K
not1 ip0703
1 Jul 16
Entry into a Material Definitive Agreement
12:00am
8-K
zkxrwh8 iw
30 Jun 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
v8vb m5rj1w
8 Jun 16
Sorrento Closes $150 Million Private Placement Investments
12:00am
8-K
1fwet
7 Jun 16
Sorrento and 3SBio Announce CAR-T Joint Venture in China
12:00am
8-K
rd37hnn
6 Jun 16
Entry into a Material Definitive Agreement
12:00am
8-K
91nzc iemp9t
26 May 16
Sorrento Therapeutics to Present at the Jefferies 2016 Healthcare Conference
12:00am
8-K
c4z2 r776
16 May 16
Sorrento Announces Positive Data from a Combined Phase 2 & 3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody
12:00am
8-K
ajn 4s267dsofj6a
9 May 16
Sorrento Therapeutics engaged advisors for exploring strategic alternatives
12:00am
8-K
h6khat
2 May 16
Sorrento to Present at 2 upcoming conferences in New York City
12:00am
8-K
p1x01rip1ut8
2 May 16
Sorrento closes private placement with Yuhan Corporation
12:00am
8-K
4f2wr
6 Apr 16
Sorrento Appoints Kevin M. Herde As Chief Financial Officer
12:00am
8-K
sc921y0 gwzd
6 Apr 16
Sorrento to Present at the Jefferies Immuno-Oncology Summit
12:00am
8-K
eg1hdvvv
5 Apr 16
Sorrento Announces Definitive Agreements for up to $150 Million Private Placement
12:00am
8-K
0l9oi27wqtlgtgf6
4 Mar 16
Sorrento to Present at the Cowen and Company 36th Annual
12:00am
8-K
wgaxa8 4o
2 Mar 16
Other Events
12:00am
8-K/A
jycr s3jyzzi5nuyz
5 Feb 16
Financial Statements and Exhibits
12:00am
8-K
k50g10n
11 Jan 16
Sorrento and Karolinska Institutet Establish Exclusive Partnership for Research and Development of Natural Killer Cell-based Therapies
12:00am
8-K
uduwkkrnlnkp exbzf
8 Jan 16
Upcoming Corporate Presentations In San Francisco
12:00am